AbCellera Biologics' stock surged 7.62% in the after-hours session following the release of its first-quarter 2026 financial results and an update on its clinical pipeline.

The biotechnology company reported a narrower-than-expected quarterly loss and revenue that significantly exceeded analyst forecasts. AbCellera posted a loss of $0.14 per share, beating the FactSet consensus estimate for a loss of $0.17 per share. Revenue for the quarter reached $8.3 million, more than doubling from the year-ago period and surpassing the $5.9 million analyst estimate.

Investors also reacted positively to interim Phase 1 clinical data for the company's drug candidate ABCL635. The data showed a favorable tolerability profile with no serious adverse events, a pharmacokinetic profile supporting once-monthly dosing, and strong evidence of target engagement. The company ended the quarter with approximately $655 million in total available liquidity to fund its development strategy.